About CN Bio
CN Bio is a company based in Cambridge (United Kingdom) founded in 2009. CN Bio has raised $44.78 million across 14 funding rounds from investors including Gov.uk, Gates Foundation and CN Innovations. The company has 33 employees as of December 31, 2020. CN Bio offers products and services including PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit. CN Bio operates in a competitive market with competitors including Emulate, AxoSim, Mimetas, Obatala Sciences and Nortis, among others.
- Headquarter Cambridge, United Kingdom
- Employees 33 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Cn Bio Innovations Limited
- Date of Incorporation 28 Feb, 2008
- Jurisdiction THAME, OXFORDSHIRE
-
Annual Revenue
$2.64 M (USD)27as on Dec 31, 2022
-
Net Profit
-$5.1 M (USD)-37as on Dec 31, 2022
-
EBITDA
Not available
-
Total Equity Funding
$44.78 M (USD)
in 14 rounds
-
Latest Funding Round
$21 M (USD), Series B
Apr 23, 2024
-
Investors
Gov.uk
& 4 more
-
Employee Count
33
as on Dec 31, 2020
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CN Bio
CN Bio offers a comprehensive portfolio of products and services, including PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit.
Hardware for recreating human biology in drug testing
Plates used in organ-on-a-chip setups for research
Cells for modeling human tissues in experiments
Kit to predict drug-induced liver injury
People of CN Bio
Unlock access to complete
Funding Insights of CN Bio
CN Bio has successfully raised a total of $44.78M across 14 strategic funding rounds. The most recent funding activity was a Series B round of $21 million completed in April 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in CN Bio
CN Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Gates Foundation and CN Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Online government services and information are provided to users.
|
Locked | Locked | Locked | |
|
Provides management consulting and business services to support organizational growth.
|
Locked | Locked | Locked |
Investor details for CN Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CN Bio
Investment portfolio details for CN Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CN Bio
Detailed financials for CN Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cn Bio Comparisons
Peer comparison for CN Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CN Bio
CN Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emulate, AxoSim, Mimetas, Obatala Sciences and Nortis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of in vitro models for drug development
|
|
| Locked | Locked | Locked |
Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement.
|
|
| Locked | Locked | Locked |
Microfluidics-based organ-on-a-chip models for drug evaluation are developed.
|
|
| Locked | Locked | Locked |
Provider of research enabling products and services to research centers
|
|
| Locked | Locked | Locked |
Small human tissue segments are generated in microfluidic chips.
|
Detailed competitors of CN Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cn Bio
Complete news archive for CN Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CN Bio
CN Bio was founded in 2009 and raised its 1st funding round 1 year after it was founded.
CN Bio is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
David Hughes is the current CEO of CN Bio.
CN Bio is a funded company, having raised a total of $44.78M across 14 funding rounds to date.
As of Dec 31, 2020, the latest employee count at CN Bio is 33.
Annual revenue of CN Bio is $2.64M as on Dec 31, 2022.
CN Bio was founded in 2009 in Cambridge, United Kingdom, and operates in the biotechnology sector focused on in vitro modeling. Organ-on-a-chip platforms, including the PhysioMimix OOC benchtop device, are provided for studies in oncology, infectious diseases, metabolism, and inflammation. These systems support investigations into drug metabolism, toxicity, drug-drug interactions, therapeutic antibodies, proteins, and cellular therapies, with specific models for liver functions and barrier tissues.
CN Bio offers PhysioMimix OOC, Multi-chip plates, 3D validated cells, and DILI assay kit.
CN Bio has 5 investors. Key investors include Gov.uk, Gates Foundation, CN Innovations, CITIC Innovation Incubation Investment, and Bayland Capital.